Given that times to recurrence and death for HR+ tumors are 5–20 years and ≥10 years, respectively, these studies may not have had sufficient follow-up time to detect survival differences in women with HR+/HER2-breast cancer; alternatively, these studies highlight the importance of provision of integrative healthcare in ameliorating the survival disadvantage of Black women in the US with HR+/HER2-breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.